Indication for Adjuvant Therapy after TUR of Superficial Bladder Carcinoma in Daily Urological Practice

2015 ◽  
pp. 208-220
Author(s):  
H. R�bben ◽  
R. Harzmann
Keyword(s):  
Adjuvant Therapy ◽  
Bladder Carcinoma ◽  
Superficial Bladder Carcinoma

Thin-Section CT with Air Insufflation Technique for Bladder Carcinoma: CT Findings of Superficial Bladder Carcinoma

1994 ◽  
Vol 30 (2) ◽  
pp. 347
Author(s):  
Mi Hye Kim ◽  
Kyung Sub Shinn ◽  
Hyun Kim ◽  
Ha Hun Song ◽  
Si Won Kang ◽  
...  
Keyword(s):  
Thin Section ◽  
Bladder Carcinoma ◽  
Ct Findings ◽  
Superficial Bladder Carcinoma ◽  
Air Insufflation

scholarly journals Bladder perforation after immediate postoperative intravesical instillation of mitomycin C

2013 ◽  
Vol 4 (1) ◽  
pp. 1 ◽  
Author(s):  
Darwin Lim ◽  
Jonathan I. Izawa ◽  
Paul Middlebrook ◽  
Joseph L. Chin
Keyword(s):  
Intensive Care ◽  
Single Dose ◽  
Mitomycin C ◽  
Male Patient ◽  
Transurethral Resection ◽  
Bladder Carcinoma ◽  
Adjunctive Therapy ◽  
Intravesical Instillation ◽  
Recurrence Rates ◽  
Superficial Bladder Carcinoma

Intravesical chemotherapy after transurethral resection of a bladdertumour (TURBT) has been observed to significantly decreaserecurrence rates compared to TURBT alone. Though immediatepostoperative intravesical treatment with chemotherapeutic agentsafter transurethral resection for superficial bladder carcinoma isgenerally considered a safe and effective adjunctive therapy indecreasing recurrence rates, its instillation is not always completelyinnocuous. Lately, a more serious complication of bladderperforation associated with immediate instillation of intravesicalmitomycin C (MMC) after TURBT was reported. We reportour own experience of a male patient with bladder perforationafter an early instillation of a single dose of MMC. In this case,systemic toxicity occurred which required intensive care aftersurgical repair.

Intravesical Doxorubicin for Superficial Bladder Carcinoma

2005 ◽  
Vol 40 (1) ◽  
pp. 31-34
Author(s):  
Dominic A. Solimando ◽  
J. Aubrey Waddell
Keyword(s):  
Bladder Carcinoma ◽  
Superficial Bladder Carcinoma

Long-Term Follow-Up of Cytostatic Intravesical Instillation in Patients with Superficial Bladder Carcinoma

1997 ◽  
Vol 31 (2) ◽  
pp. 153-159 ◽  
Author(s):  
Hartwig Schwaibold ◽  
Uwe Pichlmeier ◽  
Hans-Jörg Klingenberger ◽  
Hartwig Huland
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Superficial Bladder Carcinoma ◽  
Long Term Follow Up

Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression.

1996 ◽  
Vol 14 (6) ◽  
pp. 1778-1786 ◽  
Author(s):  
R Kaempfer ◽  
L Gerez ◽  
H Farbstein ◽  
L Madar ◽  
O Hirschman ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Mononuclear Cells ◽  
Interleukin 2 ◽  
Response To Treatment ◽  
Tumor Type ◽  
Ifn Gamma ◽  
Superficial Bladder Carcinoma

PURPOSE Superficial bladder carcinoma, treated by resection and intravesical administration of bacillus Calmette-Guérin (BCG), yields a remission rate that approaches 70%. We examined whether expression of interleukin-2 (IL-2) or interferon-gamma (IFN-gamma) genes can serve to predict response. PATIENTS AND METHODS During BCG treatment, we analyzed induction of IL-2 and IFN-gamma mRNA in peripheral-blood mononuclear cells (PBMC) from 73 patients: 51 with papillary tumors and 22 with carcinoma-in-situ (CIS). Results were correlated with remission, relapse, or tumor persistence over a 4-year follow-up period. RESULTS Independent of tumor type, induction of IL-2 mRNA was observed for patients who responded with remission, but not for those who relapsed (P = .0001). Multivariate logistic analysis showed that inducibility of IL-2 mRNA is the discriminating parameter, which yields a predictive value of 97% for remission. Of 23 patients with relapse/persistence, 22 lacked inducibility of IL-2 mRNA (sensitivity, 95.6%), while 35 of 50 patients in remission exhibited inducibility (specificity, 70%). For patients with carcinoma-in-situ, in which remission or failure depends solely on response to BCG, sensitivity and specificity were 88% and 86%, respectively; for patients with papillary tumors, they were 100% and 64%. IFN-gamma mRNA, by contrast, was clearly inducible in PBMC from all patients (P = .51). The disease-free interval increased progressively with inducibility of IL-2 mRNA; this trend was highly significant (P = .0001). CONCLUSION IL-2 gene expression is essential for mounting an antitumor response in superficial bladder carcinoma. Inducibility of IL-2 mRNA is an independent prognostic parameter and useful predictive indicator of remission versus relapse.

Sign in / Sign up

Export Citation Format

Share Document